Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Postgraduate Medicine
|
June 14, 2012
Evaluation of cognitive function in healthy older subjects treated with fesoterodine
Gary G Kay, Paul Maruff, David Scholfield, et al.
Diabetes, Obesity & Metabolism
|
January 8, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
Silvina Gallo, Bernard Charbonnel, Allison Goldman, et al.
Contemporary Clinical Trials
|
February 3, 2007
Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study
Alex Collie, Amanda Darekar, Georges Weissgerber, et al.
Journal of Pediatric Urology
|
March 16, 2012
Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder
Bimal Malhotra, Ahmed El-Tahtawy, Ellen Q Wang, et al.
Journal of Pediatric Urology
|
December 12, 2022
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study
Takeya Kitta, Amanda Darekar, Bimal Malhotra, et al.
BJU International
|
March 8, 2013
Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder
Vik Khullar, Linda Cardozo, Con J Kelleher, et al.
Journal of the American Geriatrics Society
|
January 29, 2013
Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial
Adrian Wagg, Vik Khullar, Daniela Marschall-Kehrel, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
Jie Liu, Shrita Patel, Nilo B Cater, et al.
Diabetes & Vascular Disease Research
|
May 14, 2019
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Jie Liu, Lisa Tarasenko, Steven G Terra, et al.
Diabetes, Obesity & Metabolism
|
September 1, 2017
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock, Juan Frias, Dénes Páll, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Postgraduate Medicine
|
June 14, 2012
Evaluation of cognitive function in healthy older subjects treated with fesoterodine
Gary G Kay, Paul Maruff, David Scholfield, et al.
Diabetes, Obesity & Metabolism
|
January 8, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
Silvina Gallo, Bernard Charbonnel, Allison Goldman, et al.
Contemporary Clinical Trials
|
February 3, 2007
Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study
Alex Collie, Amanda Darekar, Georges Weissgerber, et al.
Journal of Pediatric Urology
|
March 16, 2012
Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder
Bimal Malhotra, Ahmed El-Tahtawy, Ellen Q Wang, et al.
Journal of Pediatric Urology
|
December 12, 2022
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study
Takeya Kitta, Amanda Darekar, Bimal Malhotra, et al.
BJU International
|
March 8, 2013
Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder
Vik Khullar, Linda Cardozo, Con J Kelleher, et al.
Journal of the American Geriatrics Society
|
January 29, 2013
Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial
Adrian Wagg, Vik Khullar, Daniela Marschall-Kehrel, et al.
Diabetes, Obesity & Metabolism
|
December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
Jie Liu, Shrita Patel, Nilo B Cater, et al.
Diabetes & Vascular Disease Research
|
May 14, 2019
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Jie Liu, Lisa Tarasenko, Steven G Terra, et al.
Diabetes, Obesity & Metabolism
|
September 1, 2017
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock, Juan Frias, Dénes Páll, et al.
Page
of 3